A Practical Guide to Pan Coating and Scale-Up - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Practical Guide to Pan Coating and Scale-Up
An understanding of the pan-coating process based on first principles can support successful scale up.


Equipment and Processing Report


There are various theories about how to scale up a solid dosage coating operation in a pan coater. This article provides a basic process understanding and scale-up theory based on first principles.

The coating process shown in Figure 1 has multiple, simultaneous, ongoing exchange processes. The first is a heat exchange between the inlet process air and the coater metal body, spray droplets, and tablets. The second is a mass exchange between the material sprayed and the inlet air stream, tablets, and coating pan.


There are certain losses (e.g., heat loss to the metal body and the environment), however, that cannot be characterized easily. An approximate mass and energy balance for the coating process in an equilibrium state can be calculated as shown in Equations 1–3, where H = enthalpy and m = mass.

The heat balance is shown in Equation 1:


The mass balance for the solvent is shown in Equation 2:


The mass balance for the solids sprayed is shown in Equation 3:


As with any theoretical analysis, there are assumptions built into the model described above. For example:


•Leftover material in lines are not considered.
•Heat loss to equipment body and environment are not considered.
•Any unrecoverable mass loss in the process is not accounted for.

This model can be used to calculate process efficiency and efficiency of the inlet air heat capacity. Efficiency of coating will generally improve as the process is scaled up because the bed depth will be increased, thus increasing the heat exchange between the process air and the tablets.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Equipment and Processing Report,
Click here